{
  "id": "lupus-nephritis",
  "title": "Lupus Nephritis",
  "lang": "en",
  "source_lang": "en",
  "summary": "Lupus nephritis is immune-mediated kidney inflammation associated with systemic lupus erythematosus, ranging from mild urinary abnormalities to progressive kidney failure.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Lupus glomerulonephritis",
    "renal lupus"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/lupus-nephritis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/lupus-nephritis/",
      "json": "https://aiwiki.page/zh/lupus-nephritis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Lupus nephritis is kidney involvement caused by systemic lupus erythematosus (SLE), an autoimmune disease in which immune responses injure the body’s own tissues. Its characteristic lesion is inflammation of the kidney’s filtering units, although the tubules, surrounding tissue, and blood vessels may also be affected. The clinical spectrum extends from protein or blood detectable only on urine testing to nephrotic syndrome, rapidly declining kidney function, and irreversible kidney failure.\n\nLupus nephritis is a major determinant of illness and long-term outcome in SLE. Its severity cannot be established from symptoms or blood tests alone: patients with relatively modest urinary abnormalities may have substantial inflammatory injury, while persistent protein loss after treatment may reflect scarring rather than continuing inflammation. Assessment therefore combines urine measurements, kidney function, immunologic tests, and, in many cases, examination of a kidney tissue sample.\n\nThe disease is understood as a collection of related immune-mediated lesions rather than a single uniform process. Classification of these lesions guides treatment, while their activity, chronic damage, and response over time help establish prognosis. Modern management combines suppression of damaging immune responses with measures that address protein loss, blood pressure, treatment toxicity, and the consequences of chronic kidney disease."
    },
    {
      "heading": "Epidemiology and clinical setting",
      "text": "Clinically apparent kidney disease develops in approximately 30–50% of people with SLE in many adult cohorts, although estimates vary substantially with ancestry, age, follow-up duration, and the definition of renal involvement. Microscopic immune deposits can occur more frequently than clinically recognized nephritis. This distinction is important when comparing studies: a series based on kidney biopsies does not measure the same phenomenon as one based on persistent proteinuria or a decline in kidney function.\n\nKidney involvement commonly appears at the diagnosis of SLE or within the first several years, but it can occur later. In some patients, nephritis is the presenting feature that leads to recognition of systemic lupus. Others already have manifestations such as arthritis, skin disease, cytopenias, or serositis before renal abnormalities develop. Kidney and extrarenal activity do not always move together; an important renal flare can occur without a dramatic increase in symptoms elsewhere.\n\nAlthough SLE is much more common in women, men with SLE have a relatively high risk of renal involvement in many observational studies. Childhood-onset disease is also associated with a greater frequency of nephritis than adult-onset disease. Comparisons between pediatric and adult populations are complicated by differences in disease duration, referral patterns, and the intensity of surveillance. Children face the additional burden of many decades of potential disease activity and treatment exposure.\n\nStudies in the United States and elsewhere have reported greater renal disease burden among patients of African, Hispanic or Latino, Asian, and Indigenous backgrounds than among some populations of European ancestry. These broad categories encompass considerable genetic, geographic, and social diversity. They do not represent uniform biological groups. Genetic susceptibility interacts with social determinants of health, including access to specialist care, medication availability, continuity of insurance coverage, and delays in diagnosis or treatment. In some people with recent African ancestry, high-risk variants in the APOL1 gene are associated with adverse kidney outcomes, particularly certain forms of podocyte injury, but they do not account for the overall distribution of lupus nephritis.\n\nReported outcomes also depend on the setting in which patients receive care. Specialist cohorts may contain disproportionately severe disease, while populations with limited biopsy access may have underrecognized nephritis. Consequently, no single prevalence or kidney-failure estimate describes all patients with SLE. Population differences must be interpreted alongside disease severity, treatment era, and health-system factors."
    },
    {
      "heading": "Immune mechanisms and patterns of kidney injury",
      "text": "The central process in lupus nephritis is loss of immune tolerance to self-antigens, especially nuclear material. Defective clearance of dying cells and increased exposure to nucleic acids help sustain autoimmunity. B cells produce autoantibodies, including antibodies directed against double-stranded DNA and other nuclear constituents. These antibodies may form circulating immune complexes, bind material already present in the kidney, or react with components associated with renal tissue.\n\nImmune complexes accumulate in different compartments of the glomerulus, the capillary tuft within each nephron. Their location helps determine the pattern of injury. Deposits in the mesangium, the supporting tissue between capillary loops, may produce relatively limited urinary abnormalities. Deposits beneath endothelial cells, on the blood-facing side of the glomerular basement membrane, are more accessible to circulating inflammatory cells and are associated with proliferative nephritis. Deposits beneath podocytes, on the outer side of the basement membrane, are characteristic of membranous disease and often cause substantial protein leakage.\n\nActivation of the complement system amplifies tissue injury. Complement fragments recruit leukocytes and promote inflammatory signaling, while terminal complement components can damage cell membranes. The relationship is biologically complex: inherited deficiencies of some early complement components predispose to lupus because these proteins also help clear immune complexes and cellular debris. Thus, complement can protect against the development of autoimmunity while contributing to tissue injury once disease is established.\n\nInnate and adaptive immune pathways reinforce one another. Nucleic-acid sensing activates plasmacytoid dendritic cells and other cells, promoting type I interferon signaling. B-cell activating factor supports survival of autoreactive B cells. T cells, monocytes, macrophages, and locally produced cytokines contribute to glomerular and interstitial inflammation. These mechanisms explain why treatments directed at B-cell survival, lymphocyte proliferation, and broad inflammatory pathways can all influence renal disease.\n\nPersistent injury eventually produces changes that immunosuppression cannot reverse. Glomerular capillary loops become scarred, tubules atrophy, and interstitial fibrosis develops. Loss of functioning nephrons increases the workload of remaining units and may perpetuate proteinuria and progressive kidney dysfunction even after immune activity has subsided. This distinction between active, potentially reversible inflammation and chronic structural damage is fundamental to interpreting biopsy findings and treatment response."
    },
    {
      "heading": "Symptoms, urinary abnormalities, and renal syndromes",
      "text": "Lupus nephritis may be clinically silent at its onset. Protein and red blood cells can appear in the urine before swelling, high blood pressure, or reduced kidney function becomes evident. Urine dipstick testing is a screening method, but quantification is needed to characterize protein loss. A spot urine protein-to-creatinine ratio is commonly used; timed urine collection provides another approach. Variation in collection quality, muscle mass, and daily protein excretion can affect interpretation.\n\nProteinuria reflects disruption of the glomerular filtration barrier, impaired tubular protein handling, or both. Marked glomerular leakage may produce nephrotic syndrome, characterized by heavy proteinuria, low serum albumin, and often edema and elevated lipid concentrations. Swelling may involve the ankles, eyelids, or more generalized tissues. Severe nephrotic syndrome also increases susceptibility to venous thrombosis, particularly when serum albumin is very low.\n\nInflammatory glomerular disease may produce a nephritic pattern: microscopic or visible blood in the urine, proteinuria, hypertension, and reduced filtration. Urine microscopy can reveal dysmorphic red blood cells or red-cell casts, which support a glomerular source of bleeding. Casts form within renal tubules and can provide evidence of intrarenal pathology. Their absence does not exclude active disease, and urine findings can fluctuate between samples.\n\nA rise in serum creatinine may indicate acute kidney injury, progressive chronic disease, or an acute process superimposed on established damage. Severe proliferative lesions can cause rapidly worsening function over days to weeks. Conversely, membranous lupus nephritis may produce extensive protein loss while filtration remains relatively preserved. The amount of proteinuria therefore does not, by itself, identify the histologic class or establish the extent of inflammatory injury.\n\nNot every kidney abnormality in a person with SLE is lupus nephritis. Other possibilities include urinary infection, kidney stones, medication-associated injury, dehydration, diabetic kidney disease, and vascular injury. Hypertension can be both a consequence of renal disease and an additional cause of damage. Antiphospholipid-associated vascular disease may cause renal dysfunction through small-vessel lesions or larger-vessel thrombosis. Distinguishing these processes matters because similar laboratory abnormalities can arise from diseases requiring different forms of treatment."
    },
    {
      "heading": "Diagnostic assessment and kidney biopsy",
      "text": "Evaluation establishes the extent of renal involvement, looks for evidence of active systemic lupus, and examines alternative explanations for kidney abnormalities. Common measurements include serum creatinine, estimated glomerular filtration rate (eGFR), serum albumin, urine protein excretion, and urine microscopy. A complete blood count may identify associated cytopenias, while other tests assess electrolyte disturbances and complications of impaired kidney function. Trends are generally more informative than an isolated result.\n\nImmunologic testing provides supporting information rather than a direct measurement of renal inflammation. Antinuclear antibodies are highly sensitive for SLE but insufficiently specific to establish lupus nephritis. Anti-double-stranded DNA antibody concentrations may rise and complement C3 and C4 concentrations may fall during active disease. However, some patients have persistent serologic abnormalities without active nephritis, while others develop renal activity without a marked serologic change. Neither normal complement levels nor a negative anti-double-stranded DNA result excludes renal disease.\n\nKidney biopsy is central when clinically important lupus nephritis is suspected because laboratory findings do not reliably distinguish proliferative, membranous, vascular, and chronic scarred lesions. Contemporary guidance commonly considers biopsy when protein excretion reaches approximately 500 mg per day or an equivalent protein-to-creatinine ratio, particularly with active urinary sediment or otherwise unexplained impairment of kidney function. These thresholds structure clinical assessment rather than define a boundary below which important lesions cannot occur.\n\nA biopsy is evaluated by light microscopy, immunofluorescence, and, when available, electron microscopy. Light microscopy shows cellular proliferation, necrosis, crescents, capillary-wall changes, and chronic scarring. Immunofluorescence characterizes deposited immunoglobulins and complement. The classic “full-house” pattern includes IgG, IgA, IgM, C3, and C1q. Electron microscopy identifies the location and structure of deposits and may show endothelial tubuloreticular inclusions associated with interferon activity. A full-house pattern is suggestive but is not unique to lupus.\n\nBiopsy interpretation also has limitations. A small sample may miss focal lesions, and tissue obtained at one time cannot capture all subsequent evolution. Repeat biopsy can clarify selected cases of apparent relapse, unexplained decline, or persistent abnormalities when ongoing inflammation and residual damage are difficult to distinguish. Its value lies in answering a specific clinical question; neither initial nor repeat tissue examination replaces longitudinal assessment of kidney function, proteinuria, treatment exposure, and the broader clinical course."
    },
    {
      "heading": "Histologic classification and prognostic lesions",
      "text": "The International Society of Nephrology/Renal Pathology Society classification, introduced in 2003 and subsequently refined, divides lupus nephritis into six classes. These describe patterns of glomerulonephritis, not six inevitable stages through which every patient progresses. Different patterns can coexist, and the predominant class may change during subsequent disease episodes. Classification is most informative when accompanied by a detailed description of inflammatory activity, chronic damage, and lesions outside the glomeruli.\n\nClass | Principal glomerular findings | Typical clinical associations\nI: Minimal mesangial | Mesangial immune deposits without abnormalities on light microscopy | Often little or no clinically evident renal disease\nII: Mesangial proliferative | Mesangial hypercellularity or matrix expansion with mesangial deposits | Usually mild proteinuria or microscopic hematuria\nIII: Focal | Active or chronic proliferative lesions involving fewer than 50% of glomeruli | Variable proteinuria, hematuria, and impairment of filtration\nIV: Diffuse | Proliferative lesions involving at least 50% of glomeruli | Frequently substantial inflammatory disease and reduced kidney function\nV: Membranous | Predominantly subepithelial immune deposits and capillary-wall abnormalities | Often heavy proteinuria or nephrotic syndrome\nVI: Advanced sclerosing | At least 90% globally sclerosed glomeruli without residual activity | Advanced irreversible glomerular damage\n\nClasses III and IV are commonly termed proliferative lupus nephritis. Active lesions can include endocapillary hypercellularity, capillary-wall rupture, fibrinoid necrosis, and cellular crescents. Crescents arise when severe capillary injury permits inflammatory material to enter Bowman’s space, stimulating proliferation of epithelial cells and recruitment of inflammatory cells. “Wire-loop” lesions represent prominent subendothelial deposits visible by light microscopy; their striking appearance does not substitute for an overall activity assessment.\n\nClass V disease can occur alone or together with class III or IV. Mixed proliferative and membranous disease is reported as such because the proliferative component has major implications for treatment. Conversely, marked nephrotic syndrome with class I or II appearances raises the possibility of lupus podocytopathy, an uncommon pattern involving extensive podocyte foot-process effacement. This illustrates why the six-class framework does not encompass every clinically meaningful renal lesion associated with SLE.\n\nActivity and chronicity indices supply information beyond the class label. Activity scoring includes lesions such as cellular proliferation, necrosis, crescents, and interstitial inflammation. Chronicity scoring includes glomerular sclerosis, fibrous crescents, tubular atrophy, and interstitial fibrosis. Active and chronic lesions often coexist. A biopsy may therefore show severe immune injury that remains potentially treatable alongside substantial permanent loss of functioning tissue.\n\nTubulointerstitial and vascular findings also influence prognosis. Interstitial fibrosis and tubular atrophy are strongly associated with poorer long-term renal outcomes. Vascular lesions include immune deposits, arteriosclerosis, and thrombotic microangiopathy. The latter may occur in association with antiphospholipid antibodies, severe hypertension, or other mechanisms. Consequently, a complete pathology report describes more than the glomerular class: it documents the distribution of injury, its reversibility, and additional processes that may require separate interpretation."
    },
    {
      "heading": "Treatment strategies and supporting trial evidence",
      "text": "Treatment depends on histologic pattern, disease activity, kidney function, proteinuria, and the extent of chronic damage. Active class III or IV disease generally receives immunosuppression, whereas advanced irreversible scarring is not expected to improve through intensification of immune therapy. Pure class V disease is approached differently according to the severity of protein loss and its complications. Across these patterns, the objective is to control inflammation, preserve functioning nephrons, and limit cumulative treatment toxicity.\n\nGlucocorticoids rapidly suppress inflammatory pathways and remain part of many initial regimens. Severe presentations may be treated with intravenous methylprednisolone followed by oral therapy. Modern strategies emphasize lower cumulative exposure and more rapid dose reduction than many historical regimens because prolonged glucocorticoid treatment contributes to infection, diabetes, osteoporosis, and cardiovascular damage. Glucocorticoids are generally combined with another immunosuppressive agent rather than relied upon alone for active proliferative disease.\n\nMycophenolate-based treatment and intravenous cyclophosphamide are established options for initial therapy. Mycophenolate inhibits inosine monophosphate dehydrogenase and thereby restricts guanine nucleotide synthesis, to which activated lymphocytes are particularly sensitive. Cyclophosphamide is an alkylating agent that suppresses proliferating immune cells. The Euro-Lupus regimen uses six fixed 500-mg intravenous cyclophosphamide doses given two weeks apart, followed by maintenance therapy. The ALMS induction study, published in 2009, found similar overall response rates with mycophenolate mofetil and intravenous cyclophosphamide, supporting both as major treatment options.\n\nTargeted agents have expanded combination treatment. Belimumab, a monoclonal antibody that inhibits B-cell activating factor, was evaluated in the BLISS-LN trial, published in 2020. At 104 weeks, its addition to standard therapy increased the primary efficacy renal response from approximately 32% to 43%. Voclosporin, a calcineurin inhibitor, was evaluated in AURORA 1, published in 2021, alongside mycophenolate and a rapidly tapered glucocorticoid regimen. Complete renal response at 52 weeks occurred in approximately 41% of the voclosporin group and 23% of the control group. These percentages cannot be directly compared because the trials used different populations, durations, and response definitions.\n\nAfter initial control, maintenance treatment reduces the likelihood of relapse. Mycophenolate is commonly used, while azathioprine remains important in circumstances including pregnancy planning. Hydroxychloroquine is generally part of SLE care unless contraindicated and is associated with lower flare risk. Kidney-protective treatment often includes blood-pressure control and reduction of proteinuria through blockade of the renin–angiotensin–aldosterone system. Treatment selection also incorporates drug interactions, reproductive considerations, infection risk, and the feasibility of sustained monitoring."
    },
    {
      "heading": "Response assessment, relapse, and treatment complications",
      "text": "Treatment response is assessed through changes in proteinuria, kidney function, urinary sediment, and the wider clinical picture. Serologic markers can support interpretation but are not sufficient on their own. Complete renal response in trials and guidelines usually combines low protein excretion with stable or improved kidney function, sometimes with requirements concerning glucocorticoid dose or absence of rescue treatment. Partial response generally involves a substantial reduction in proteinuria without clinically important deterioration of filtration. Exact definitions differ, limiting direct comparisons between studies.\n\nThe rate of improvement matters, but recovery is not instantaneous. Proteinuria may decline over many months as inflammation resolves and the filtration barrier recovers. Commonly used treatment milestones include a substantial early reduction and protein excretion approaching less than 0.5–0.7 g per day by about 12 months, although baseline nephrotic-range proteinuria can take longer to resolve. These milestones are prognostic tools, not proof of histologic remission. Some patients with an apparent clinical response retain inflammatory lesions, while others have residual proteinuria from chronic damage.\n\nRelapse may present with renewed proteinuria, active urine sediment, or worsening kidney function after an earlier response. Evaluation distinguishes a true immune flare from infection, medication toxicity, altered blood pressure, vascular disease, and inconsistent medication exposure. Difficulty taking treatment may reflect adverse effects, cost, complex dosing, misunderstanding, or disrupted care rather than a single behavioral cause. Repeat biopsy can be useful when this distinction would materially affect treatment, particularly because recurrent disease can have a different histologic pattern.\n\nInfection is a major treatment-related hazard. Risk reflects the combined effects of immune dysfunction, glucocorticoids, other immunosuppressants, reduced kidney function, and comorbid disease. Bacterial infection, herpes zoster, and opportunistic infections are clinically important. Infection-prevention practices in specialist care include vaccination assessment, screening for selected latent infections, and antimicrobial prophylaxis in particular high-risk treatment settings. Infection can also mimic lupus activity, making accurate attribution essential before immune therapy is intensified.\n\nOther toxicities differ among agents. Cyclophosphamide can cause marrow suppression, bladder injury, gonadal toxicity, and a dose-related risk of later malignancy. Mycophenolate can cause gastrointestinal effects and cytopenias and is associated with major fetal risk. Calcineurin inhibitors can reduce filtration through hemodynamic effects, raise blood pressure, and cause nephrotoxicity. Hydroxychloroquine exposure requires attention to retinal toxicity, particularly when kidney impairment alters drug handling. Long-term care therefore measures success not simply by suppression of nephritis but also by the burden of complications generated during its treatment."
    },
    {
      "heading": "Childhood disease, pregnancy, and advanced kidney failure",
      "text": "Childhood-onset lupus nephritis uses the same general pathologic framework as adult disease, but its consequences occur during growth, schooling, and pubertal development. Glucocorticoid exposure can affect growth and bone health, while gonadotoxic treatment may influence future fertility. Pediatric regimens often draw partly on adult trial evidence because children have been underrepresented in large studies. Transition from pediatric to adult services is an important period for continuity of medication access, monitoring, and specialist follow-up.\n\nPregnancy in a patient with lupus nephritis involves interactions among renal disease activity, baseline kidney function, hypertension, antiphospholipid antibodies, and medication exposure. Active nephritis is associated with increased risks of maternal disease flare, preterm delivery, impaired fetal growth, and pregnancy loss. Some drugs used for nephritis, notably mycophenolate, are incompatible with pregnancy because of fetal toxicity. Hydroxychloroquine, azathioprine, and certain calcineurin inhibitors have established roles in pregnancy-compatible management under specialist supervision.\n\nA particularly difficult diagnostic problem is distinguishing a lupus nephritis flare from preeclampsia, which usually develops after 20 weeks of gestation and can also cause hypertension, proteinuria, and kidney dysfunction. Active urinary sediment, changing anti-double-stranded DNA antibodies, low complement, and extrarenal lupus manifestations may support nephritis, but no single finding is decisive. The conditions can coexist. Interpretation depends on gestational timing, previous renal measurements, clinical findings, and obstetric assessment.\n\nIrreversible kidney failure requires kidney replacement therapy when complications can no longer be managed adequately through residual renal function. Both hemodialysis and peritoneal dialysis are used in people with lupus. Extrarenal lupus activity sometimes decreases after kidney failure develops, but this is not universal. Continued immune treatment may remain necessary for nonrenal manifestations, while infection risk and altered drug clearance complicate its use.\n\nKidney transplantation is an established treatment for suitable patients with kidney failure due to lupus nephritis. Outcomes are generally favorable when systemic disease is controlled. Recurrent lupus-related immune deposits can occur in the graft, sometimes without clinically important dysfunction; severe recurrence is less common than histologic recurrence. Graft outcomes also depend on rejection, infection, cardiovascular disease, and thrombotic risk. Kidney failure therefore changes the clinical setting of lupus care rather than eliminating the need to assess systemic disease and its associated complications."
    },
    {
      "heading": "Prognosis, historical development, and unresolved questions",
      "text": "The outlook for lupus nephritis improved substantially with the introduction of glucocorticoids, cyclophosphamide-based regimens, maintenance immunosuppression, and better supportive renal care. Studies conducted at the US National Institutes of Health helped establish that adding cyclophosphamide to glucocorticoids could preserve kidney function better than glucocorticoids alone in severe disease. Later trials examined lower cyclophosphamide exposure, alternatives such as mycophenolate, and targeted combination therapies. These changes shifted research toward preserving long-term function while reducing treatment-related damage.\n\nNevertheless, a meaningful minority of patients develop kidney failure. Long-term cohorts and pooled studies commonly report risks in the approximate range of 10–20% over 10 years, with substantial variation by population, severity, treatment era, and follow-up methods. Poorer outcomes are associated with impaired kidney function at presentation, substantial chronic damage on biopsy, persistent proteinuria, recurrent flares, and inadequate disease control. A rapid and sustained reduction in proteinuria is associated with better subsequent renal outcomes, although it does not perfectly predict them for an individual patient.\n\nRenal prognosis is only one component of overall outcome. Chronic kidney disease, persistent inflammation, hypertension, dyslipidemia, and treatment exposure contribute to cardiovascular disease. Infection is another major cause of serious illness and death. Fatigue, work disruption, treatment burden, and reproductive concerns affect quality of life even when filtration is preserved. These outcomes are not fully captured by a trial endpoint based on urine protein and creatinine.\n\nAn important unresolved issue is how to identify residual inflammatory activity without repeated biopsy. Investigational urinary and blood biomarkers include chemokines, complement activation products, immune-cell signatures, and proteins associated with tubular injury. Single-cell and spatial molecular studies have revealed diverse inflammatory cell states within affected kidneys. Such findings may help explain why patients with the same histologic class respond differently, but molecular associations require validation before they can reliably determine routine treatment choices.\n\nOther open questions concern the optimal duration of maintenance treatment, safe withdrawal of therapy, and selection among increasingly complex combinations. Proteinuria reduction is an important surrogate endpoint, yet a drug may reduce urinary protein partly through effects on glomerular pressure or podocyte function rather than complete suppression of inflammation. Trials lasting one or two years may therefore leave uncertainty about decades-long kidney preservation. Longer follow-up, more representative enrollment, and better integration of clinical, tissue, and patient-reported outcomes remain central to evaluating treatment strategies."
    }
  ],
  "links": [
    "systemic-lupus-erythematosus",
    "autoimmune-disease",
    "social-determinants-of-health",
    "autoimmunity",
    "complement-system",
    "plasmacytoid-dendritic-cell",
    "t-cell",
    "cytokine",
    "fibrosis",
    "edema",
    "hypertension",
    "complete-blood-count",
    "antinuclear-antibody",
    "biopsy",
    "glomerulonephritis",
    "immunosuppression",
    "corticosteroid",
    "monoclonal-antibody",
    "hydroxychloroquine",
    "renin-angiotensin-aldosterone-system",
    "opportunistic-infection",
    "pregnancy",
    "organ-transplantation",
    "chronic-kidney-disease",
    "cardiovascular-disease",
    "quality-of-life",
    "biomarker",
    "surrogate-endpoint"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}